Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 22, 2022

SELL
$7.89 - $17.88 $408,189 - $925,021
-51,735 Closed
0 $0
Q1 2022

Apr 06, 2022

BUY
$11.56 - $19.76 $242,413 - $414,367
20,970 Added 68.16%
51,735 $841,000
Q3 2021

Oct 12, 2021

SELL
$14.21 - $17.65 $152,686 - $189,649
-10,745 Reduced 25.89%
30,765 $442,000
Q2 2021

Jul 08, 2021

SELL
$9.5 - $17.24 $29,545 - $53,616
-3,110 Reduced 6.97%
41,510 $656,000
Q1 2021

Apr 09, 2021

SELL
$7.37 - $13.61 $130,154 - $240,352
-17,660 Reduced 28.36%
44,620 $454,000
Q4 2020

Jan 12, 2021

SELL
$3.37 - $8.61 $9,469 - $24,194
-2,810 Reduced 4.32%
62,280 $464,000
Q3 2020

Oct 06, 2020

BUY
$3.43 - $5.53 $223,258 - $359,947
65,090 New
65,090 $224,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.57B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track First Hawaiian Bank Portfolio

Follow First Hawaiian Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Hawaiian Bank, based on Form 13F filings with the SEC.

News

Stay updated on First Hawaiian Bank with notifications on news.